Livedoid vasculitis
I- Livedoid vasculitis sisifo esinganyangekiyo sesikhumba esibonwa ikakhulu kwabasetyhini abancinci ukuya kwabakwiminyaka ephakathi. Enye i-acronym esetyenziselwa ukuchaza iimpawu zayo "Izilonda ezibuhlungu ze-purpuric kunye nepateni ye-reticular yeendawo ezisezantsi" (PURPLE). Idityaniswa nenani lezifo, kubandakanywa uxinzelelo lwegazi olungapheliyo kunye ne-varicosities.
☆ Kwiziphumo zika-2022 ze-Stiftung Warentest ezivela eJamani, ukwaneliseka kwabathengi ngeModelDerm bekungaphantsi kancinci kunokubonisana nge-telemedicine ehlawulweyo.
Inokukhatshwa yintlungu.
References
Livedoid vasculopathy yimeko yesikhumba enqabileyo ebonakaliswe zizilonda ezibuhlungu ezihlala zibuyela kwimilenze engezantsi.
Livedoid vasculopathy (LV) is a rare thrombotic vasculopathy of the dermis characterized by painful, relapsing ulcers over the lower extremities. Diagnosis is challenging due to the overlap in clinical appearance and nomenclature with other skin disorders. Treatment selection is complicated by poor understanding of the pathogenesis of LV and lack of robust clinical trials evaluating therapy efficacy. The terminology and pathophysiology of LV are reviewed here, along with its epidemiology, clinical and histologic features, and treatment options. A diagnostic pathway is suggested to guide providers in evaluating for comorbidities, referring to appropriate specialists, and choosing from the available classes of therapy.
Livedoid vasculopathy (LV) is a rare thrombotic vasculopathy of the dermis characterized by painful, relapsing ulcers over the lower extremities. Diagnosis is challenging due to the overlap in clinical appearance and nomenclature with other skin disorders. Treatment selection is complicated by poor understanding of the pathogenesis of LV and lack of robust clinical trials evaluating therapy efficacy. The terminology and pathophysiology of LV are reviewed here, along with its epidemiology, clinical and histologic features, and treatment options. A diagnostic pathway is suggested to guide providers in evaluating for comorbidities, referring to appropriate specialists, and choosing from the available classes of therapy.
Livedoid vasculopathy yimeko yolusu enqabileyo ebangela izilonda eziphinda-phindayo kumazantsi emilenze, ishiya ngasemva amanxeba amnyama aziwa ngokuba yi-atrophie blanche. Ngelixa oyena nobangela ungekacaci, kukholelwa ukuba ukonyuka kweblood clotting (hypercoagulability) yeyona nto iphambili, ukudumba kudlala indima yesibini. Izinto ezinegalelo ekujikeni ziquka oku kulandelayo - deficiencies in proteins C and S, genetic mutations like factor V Leiden, antithrombin III deficiency, prothrombin gene mutations, high levels of homocysteine. Kwi-biopsies, imeko ibonisa amahlwili egazi ngaphakathi kwemithambo, ukujiya kweendonga zenqanawa, kunye nokonakala. Unyango lubandakanya iindlela ezininzi ezijolise ekuthinteleni amahlwili egazi ngamayeza afana neziyobisi ezichasene neplatelet, i-blood thinners, kunye nonyango lwe-fibrinolytic. Amachiza ahlukeneyo angasetyenziselwa le meko yolusu - colchicine and hydroxychloroquine, vasodilators, immunosuppressants.
Livedoid vasculopathy is a rare skin condition that causes recurring ulcers on the lower legs, leaving behind pale scars known as atrophie blanche. While the exact cause is still unclear, it's believed that increased blood clotting (hypercoagulability) is the main factor, with inflammation playing a secondary role. Factors contributing to clotting include as follows - deficiencies in proteins C and S, genetic mutations like factor V Leiden, antithrombin III deficiency, prothrombin gene mutations, high levels of homocysteine. In biopsies, the condition shows blood clots inside vessels, thickening of vessel walls, and scarring. Treatment involves a multi-pronged approach focusing on preventing blood clots with medications like anti-platelet drugs, blood thinners, and fibrinolytic therapy. Various drugs can be used for this skin condition - colchicine and hydroxychloroquine, vasodilators, immunosuppressants.
Livedoid vasculopathy is a rare skin condition that causes recurring ulcers on the lower legs, leaving behind pale scars known as atrophie blanche. While the exact cause is still unclear, it's believed that increased blood clotting (hypercoagulability) is the main factor, with inflammation playing a secondary role. Factors contributing to clotting include as follows - deficiencies in proteins C and S, genetic mutations like factor V Leiden, antithrombin III deficiency, prothrombin gene mutations, high levels of homocysteine. In biopsies, the condition shows blood clots inside vessels, thickening of vessel walls, and scarring. Treatment involves a multi-pronged approach focusing on preventing blood clots with medications like anti-platelet drugs, blood thinners, and fibrinolytic therapy. Various drugs can be used for this skin condition - colchicine and hydroxychloroquine, vasodilators, immunosuppressants.
Livedoid vasculopathy yimeko enqabileyo apho izilonda zenzeka kwimilenze yomibini. Ukubunjwa kwamahlwili egazi kwimithanjana encinci yegazi kucingelwa ukuba kubangelwa kukunyuka kwe-clotting kunye nokunciphisa i-clot breakdown, kunye nomonakalo kwisitya somkhumbi. Ixhaphake kakhulu kwabasetyhini, ngakumbi phakathi kweminyaka eyi-15 kunye ne-50. Ukuyeka ukutshaya, ukukhathalela amanxeba, kunye nokusebenzisa amayeza afana ne-blood thinners kunye ne-antiplatelet drugs ziye zasebenza.
Livedoid vasculopathy is a rare vasculopathy that is typically characterized by bilateral lower limb lesions. Increased thrombotic activity and decreased fibrinolytic activity along with endothelial damage are believed to be the cause of thrombus formation in the capillary vasculature. It is 3 times more common in females than in males, especially in patients between the ages of 15 to 50 years. There is no definite first-line treatment, but general measures like smoking cessation, wound care, and pharmacological measures like anticoagulants and antiplatelets have shown good results.
Livedoid vasculopathy is a rare vasculopathy that is typically characterized by bilateral lower limb lesions. Increased thrombotic activity and decreased fibrinolytic activity along with endothelial damage are believed to be the cause of thrombus formation in the capillary vasculature. It is 3 times more common in females than in males, especially in patients between the ages of 15 to 50 years. There is no definite first-line treatment, but general measures like smoking cessation, wound care, and pharmacological measures like anticoagulants and antiplatelets have shown good results.
